ABCL · AbCellera Biologics Inc.
$5.97
+0.17 (+2.93%)
At close · Jul 21
Market Cap
$1.82B
Shares
305.38M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-07-06 | 2026-06-30 | |
| Investor Event Transcript | 2026-06-30 | — | |
| Investor Event Transcript | 2026-06-30 | — | |
| 8-K | 2026-06-17 | — | |
| 8-K | 2026-06-12 | 2026-06-11 | |
| 8-K | 2026-06-05 | 2026-06-01 | |
| 10-Q | 2026-05-11 | 2026-03-31 | |
| 8-K | 2026-05-11 | — | |
| DEF 14A | 2026-04-29 | 2025-12-31 | |
| 10-K | 2026-02-24 | 2025-12-31 | |
| 8-K | 2026-02-24 | — | |
| 8-K | 2026-01-14 | 2026-01-12 | |
| 8-K | 2025-12-18 | — | |
| 8-K | 2025-11-28 | 2025-11-24 | |
| 8-K | 2025-11-12 | 2025-11-10 | |
| 10-Q | 2025-11-06 | 2025-09-30 | |
| 8-K | 2025-11-06 | — | |
| 8-K | 2025-09-10 | — | |
| 8-K | 2025-08-07 | — | |
| 10-Q | 2025-08-07 | 2025-06-30 | |
| 8-K | 2025-06-13 | 2025-06-12 | |
| 8-K | 2025-05-30 | — | |
| 8-K | 2025-05-14 | — | |
| 8-K | 2025-05-13 | 2025-05-12 | |
| 10-Q | 2025-05-08 | 2025-03-31 | |
| 8-K | 2025-05-08 | — | |
| DEF 14A | 2025-04-29 | 2024-12-31 | |
| 10-K | 2025-02-27 | 2024-12-31 | |
| 8-K | 2025-02-27 | — | |
| 8-K | 2025-02-18 | — | |
| 8-K | 2024-11-04 | — | |
| 10-Q | 2024-11-04 | 2024-09-30 | |
| 8-K | 2024-08-06 | — | |
| 10-Q | 2024-08-06 | 2024-06-30 | |
| 8-K | 2024-06-13 | — | |
| 10-Q | 2024-05-07 | 2024-03-31 | |
| 8-K | 2024-05-07 | — | |
| DEF 14A | 2024-04-29 | 2023-12-31 | |
| 8-K | 2024-02-23 | 2024-02-16 | |
| 10-K | 2024-02-20 | 2023-12-31 | |
| 8-K | 2024-02-20 | — | |
| 8-K | 2023-11-28 | — | |
| 10-Q | 2023-11-02 | 2023-09-30 | |
| 8-K | 2023-11-02 | — | |
| 8-K | 2023-10-13 | 2023-09-18 | |
| 8-K | 2023-08-03 | — | |
| 10-Q | 2023-08-03 | 2023-06-30 | |
| 8-K | 2023-06-20 | 2023-06-15 | |
| 8-K | 2023-05-24 | — | |
| 8-K | 2023-05-04 | — |
Showing 1–50 of 89 filings
Key facts
CIK
1703057
CUSIP
00288U106
13F (30d)
11 filings
11 filers
Visit website
Investor relations